Predictors of Complete Early Virological Response to Pegylated Interferon and Ribavirin in Egyptian Patients with Chronic Hepatitis C Genotype 4


We aim to determine the baseline factors associated with partial and cEVR by analyzing the data of 1861 Egyptian patients treated for 12 weeks with a course of Peg-IFN plus RBV. Base line data of 1861 Egyptian patients with chronic hepatitis C coming at Cairo-Fatemic Hospital for HCV treatment were studied including full clinical, Ultrasonographic examination, laboratory evaluation and liver biopsy. The most significant variables in relation to complete early virological response were low Hb level (<13 gm/dl) with p < 0.01, the stage of fibrosis p value < 0.05 and the grades of inflammation p value < 0.05 were associated with less achievement of c EVR. We conclude that identifying the most significant predictors of response such as Hb, stage of fibrosis F, at baseline before initiating treatment is mandatory to predict which patient will be more expected to achieve a cEVR and thus reducing the side-effects and healthcare costs associated with interferon therapies.

Share and Cite:

G. Gamil, M. Raziky, R. Salama, W. Akel, W. Fathalah and D. Attia, "Predictors of Complete Early Virological Response to Pegylated Interferon and Ribavirin in Egyptian Patients with Chronic Hepatitis C Genotype 4," Advances in Infectious Diseases, Vol. 3 No. 2, 2013, pp. 78-83. doi: 10.4236/aid.2013.32012.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Egyptian National Control Strategy for Viral Hepatitis, 2008-2012.
[2] G. M. Lauer and B. D. Walke, “Hepatitis C Virus Infection,” The New England Journal of Medicine, Vol. 345, 2001, pp. 41-52. doi:10.1056/NEJM200107053450107
[3] K. W. Ray, “Global Epidemiology and Burden of Hepatitis C,” Microbes and Infection, Vol. 4, No. 12, 2002, pp. 1219-1225. doi:10.1016/S1286-4579(02)01649-0
[4] J. Stephanos, S. Hoel Jr., R. Timothy, D. Vijayan, et al., “Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C: A Randomized Study of Treatment Duration and Ribavirin Dose,” Annals of Internal Medicine, Vol. 140, No. 5, 2004, pp. 346-355. doi:10.7326/0003-4819-140-5-200403020-00010
[5] M. P. Manns, J. G. McHutchison, S. C. Gordon, V. K. Rustgi, et al., “Peginterferon Alfa-2b plus Ribavirin Compared with Interferon Alfa-2b plus Ribavirin for Initial Treatment of Chronic Hepatitis C: A Randomised Trial,” Lancet, Vol. 358, No. 9286, 2001, pp. 958-965. doi:10.1016/S0140-6736(01)06102-5
[6] S. S. Lee, E. J. Heathcote, K. R. Reddy, S. Zeuzem, et al., “Prognostic Factors and Early Predictability of Sustained Viral Response with Peginterferon Alfa-2a (40KD),” Journal of Hepatology, Vol. 37, No. 4, 2002, pp. 500-506. doi:10.1016/S0168-8278(02)00211-8
[7] G. L. Davis, J. B. Wong, J. G. McHutchison, M. P. Manns, et al., “Early Virologic Response to Treatment With Peginterferon Alfa-2b plus Ribavirin in Patients with Chronic Hepatitis C,” Hepatology, Vol. 38, No. 3, 2003, pp. 645-652. doi:10.1053/jhep.2003.50364
[8] N. Akuta, F. Suzuki, Y. Kawamura, H. Yatsuji, et al., “Predictive Factors of Early and Sustained Responses to Peginterferon plus Ribavirin Combination Therapy in Japanese Patients Infected with Hepatitis C Virus Genotype 1b: Amino Acid Substitutions in the Core Region and Low-Density Lipoprotein Cholesterol Levels,” Journal of Hepatology, Vol. 46, No. 3, 2007, pp. 403-410. doi:10.1016/j.jhep.2006.09.019
[9] M. W. Fried, M. L. Shiffman, K. R. Reddy, et al., “Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection,” The New England Journal of Medicine, Vol. 347, No. 13, 2002, pp. 975-982. doi:10.1056/NEJMoa020047
[10] K. L. Lindsay, C. Morishima, E. C. Wright, J. L. Dienstag, et al., “Blunted Cytopenias and Weight Loss: New Correlates of Virologic Null Response to Re-Treatment of Chronic Hepatitis C,” Clinical Gastroenterology and Hepatology, Vol. 6, No. 2, 2008, pp. 234-241. doi:10.1016/j.cgh.2007.11.020
[11] C.-T. Wai, J. K. Greenson, R. J. Fontana, J. D. Kalbfleisch, et al., “A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients with Chronic Hepatitis C,” Hepatology, Vol. 38, No. 2, 2003, pp. 518-526. doi:10.1053/jhep.2003.50346
[12] M. Rodriguez-Torres, M. S. Sulkowski, R. T. Chung, F. M. Hamzeh and D. M. Jensen, “Factors Associated with Rapid and Early Virologic Response to Peginterferon Alfa-2a/Ribavirin Treatment in HCV Genotype 1 Patient’s Representative of the General Chronic Hepatitis C Population,” Journal of Viral Hepatitis, Vol. 17, No. 2, 2010, pp. 139-147. doi:10.1111/j.1365-2893.2009.01157.x
[13] M. Martinot-Peignoux, N. Boyer, M. Pouteau, C. Castelnau, et al., “Predictors of Sustained Response to Alpha Interferon Therapy in Chronic Hepatitis C,” Journal of Hepatology, Vol. 29, No. 2, 1998, pp. 214-223. doi:10.1016/S0168-8278(98)80006-8
[14] A. A. Abdo and F. M. Sanai, “Predictors of Sustained Virologic Response in Hepatitis C Genotype 4: Beyond the Usual Suspects,” Annals of Saudi Medicine, Vol. 29, 1, 2009, pp. 1-3. doi:10.4103/0256-4947.51810
[15] I. Namiki, A. Yasuhiro and K. Masayuki, “Predictors of Virological Response to a Combination Therapy with Pegylated Interferon plus Ribavirin Including Virus and Host Factors,” Hepatitis Research and Treatment, Vol. 2010, 2010, 7 Pages.
[16] S. Males, R. R. Gad, G. Esmat and H. Abobakr, “Serum Alpha-Foetoprotein Level Predicts Treatment Outcome in Chronic Hepatitis C,” Antiviral Therapy, Vol. 12, No. 5, 2007, pp. 797-803.
[17] M. F. Derbala, S. R. Al Kaabi, N. Z. El Dweik and F. Passic, “Treatment of Hepatitis C Virus Genotype 4 with Peginterferon Alfa-2a: Impact of Bilharziasis and Fibrosis Stage,” World Journal of Gastroenterology, Vol. 12, No. 35, 2006, pp. 5692-5698.
[18] A. Ascione, M. De Luca, M. T. Tartaglione, F. Lampasi, et al., “Peginterferon Alfa-2a plus Ribavirin Is More Effective than Peginterferon Alfa-2b plus Ribavirin for Treating Chronic Hepatitis C Virus Infection,” Gastroenterology, Vol. 138, No. 1, 2010, pp. 116-122. doi:10.1053/j.gastro.2009.10.005
[19] B. O. De Careaga, “Predictive Factors for Response to Treatment of Chronic Hepatitis C,” Annals of Hepatology, Vol. 5, Suppl. 1, 2006, pp. s24-s28.
[20] J. A. Mata-Marín, J. L. Fuentes-Allen, J. Gaytán-Martínez, B. Manjarrez-Téllez, et al., “APRI as a Predictor of Early Viral Response in Chronic Hepatitis C Patients,” World Journal of Gastroenterology, Vol. 15, No. 3, 2009, pp. 4923-4927. doi:10.3748/wjg.15.4923

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.